Extended-release systems and matrix tablets were fully explored in this investigation. Losartan potassium is a good option for an extended-release dosage form because it has the right combination of ingredients. The tablets formed during precompression had a free-flowing physical combination and release kinetics were examined. At the conclusion of the 8thhour, Formulation F9 was determined to be 94.09 % drug release, which was within the USP limit. In mild to moderate hypertension, potassiumlosartan has similar efficacy to enalapril, atenolol, and felodipine extended release. There were no significant differences in release profiles between the enhanced formulation and an existing commercially available product. Nonfickian (anomalous) diffusion was revealed to be the drug release mechanism for formulation F9. In-vivo pharmacokinetic studies are required to confirm these results

Losartan potassium, Formulation F9, Drug release, Extended-release matrix tablet